MED · Medifast Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $76.04M | - | $89.41M | $105.56M | $115.73M | - | $140.16M | $168.56M | $174.74M | - |
| Cost of Revenue | $24.29M | - | $27.25M | $28.91M | $31.48M | - | $34.49M | $45.12M | $47.45M | - |
| Gross Profit | $51.76M | - | $62.16M | $76.64M | $84.25M | - | $105.67M | $123.44M | $127.29M | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $55.05M | - | $66.24M | $77.71M | $85.51M | - | $103.57M | $131.31M | $119.35M | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $3.48M | - | - | - | $3.28M | - | - | - | $3.26M | - |
| Operating Income | ($3.29M) | - | ($4.08M) | ($1.07M) | ($1.26M) | - | $2.11M | ($7.88M) | $7.94M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $181.0K | - | ($396.0K) | $395.0K | $1.30M | - | $449.0K | ($2.50M) | $3.27M | - |
| Net Income | ($2.12M) | - | ($2.26M) | $2.48M | ($772.0K) | - | $1.13M | ($8.15M) | $8.32M | - |
| EPS - Basic | ($0.19) | - | ($0.21) | $0.23 | ($0.07) | - | $0.10 | ($0.75) | $0.76 | - |
| EPS - Diluted | ($0.19) | - | ($0.21) | $0.22 | ($0.07) | - | $0.10 | ($0.75) | $0.76 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $71.53M | $89.30M | $99.53M | $101.69M | $91.72M | $90.93M | $115.31M | $108.02M | $97.47M | $94.44M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | $21.40M | $20.23M | $23.20M | $30.20M | $39.36M | $42.42M | $40.09M | $39.60M | $46.27M | $54.59M |
| Accounts Payable | - | $15.07M | - | - | - | $23.05M | - | - | - | $39.19M |
| Current Assets | $202.63M | $201.68M | $207.84M | $206.44M | $213.52M | $214.40M | $224.97M | $224.31M | $219.58M | $224.03M |
| Total Assets | $252.05M | $247.97M | $268.21M | $269.33M | $280.01M | $284.21M | $291.24M | $293.53M | $302.76M | $309.91M |
| Current Liabilities | $42.18M | $42.96M | $46.71M | $46.18M | $60.60M | $64.16M | $72.38M | $75.18M | $77.19M | $92.30M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $54.37M | $49.05M | $53.50M | $53.33M | $69.05M | $74.10M | $83.89M | $88.25M | $91.80M | $108.43M |
| Stockholders' Equity | $197.68M | $198.92M | $214.71M | $216.00M | $210.96M | $210.11M | $207.34M | $205.28M | $210.96M | $201.48M |
| Retained Earnings | $156.15M | $158.27M | $176.24M | $178.49M | $176.01M | $176.78M | $175.98M | $174.84M | $182.97M | $174.65M |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $260.0K | - | - | - | $3.41M | - | - | - | $7.28M | - |
| Investing Cash Flow | ($17.13M) | - | - | - | ($2.05M) | - | - | - | ($2.77M) | - |
| Financing Cash Flow | ($901.0K) | - | - | - | ($563.0K) | - | - | - | ($1.49M) | - |
| CapEx | $1.10M | - | - | - | $1.52M | - | - | - | $1.84M | - |
| Free Cash Flow | ($836.0K) | - | - | - | $1.88M | - | - | - | $5.44M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 68.1% | - | 69.5% | 72.6% | 72.8% | - | 75.4% | 73.2% | 72.8% | - |
| Operating margin | -4.3% | - | -4.6% | -1.0% | -1.1% | - | 1.5% | -4.7% | 4.5% | - |
| EBITDA margin | 0.2% | - | - | - | 1.7% | - | - | - | 6.4% | - |
| Net margin | -2.8% | - | -2.5% | 2.3% | -0.7% | - | 0.8% | -4.8% | 4.8% | - |
| Free cash flow margin | -1.1% | - | - | - | 1.6% | - | - | - | 3.1% | - |
| FCF / Net income | 0.39 | - | - | - | -2.44 | - | - | - | 0.65 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 72.4% | - | 74.1% | 73.6% | 73.9% | - | 73.9% | 77.9% | 68.3% | - |
| Effective tax rate | - | - | - | 13.7% | 246.8% | - | 28.5% | - | 28.2% | - |
| Return on assets | -0.8% | - | -0.8% | 0.9% | -0.3% | - | 0.4% | -2.8% | 2.7% | - |
| Return on equity | -1.1% | - | -1.1% | 1.1% | -0.4% | - | 0.5% | -4.0% | 3.9% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 4.80 | 4.69 | 4.45 | 4.47 | 3.52 | 3.34 | 3.11 | 2.98 | 2.84 | 2.43 |
| Quick ratio | 4.30 | 4.22 | 3.95 | 3.82 | 2.87 | 2.68 | 2.55 | 2.46 | 2.25 | 1.84 |
| Cash ratio | 1.70 | 2.08 | 2.13 | 2.20 | 1.51 | 1.42 | 1.59 | 1.44 | 1.26 | 1.02 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.28 | 1.25 | 1.25 | 1.25 | 1.33 | 1.35 | 1.40 | 1.43 | 1.44 | 1.54 |
| Liabilities / Assets | 0.22 | 0.20 | 0.20 | 0.20 | 0.25 | 0.26 | 0.29 | 0.30 | 0.30 | 0.35 |
| Efficiency | ||||||||||
| Asset turnover | 0.30 | - | 0.33 | 0.39 | 0.41 | - | 0.48 | 0.57 | 0.58 | - |
| Inventory turnover | 1.13 | - | 1.17 | 0.96 | 0.80 | - | 0.86 | 1.14 | 1.03 | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 322d | - | 311d | 381d | 456d | - | 424d | 320d | 356d | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | 63.9x | - | - | 191.4x | - | 50.4x | - |
| P / B | 0.6x | - | 0.7x | 0.7x | 0.7x | - | 1.0x | 1.2x | 2.0x | - |
| P / S | 1.5x | - | 1.7x | 1.5x | 1.3x | - | 1.5x | 1.4x | 2.4x | - |
| EV / EBITDA | 216.1x | - | - | - | 27.7x | - | - | - | 28.8x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -34.3% | - | -36.2% | -37.4% | -33.8% | - | -40.6% | -62.8% | -58.2% | - |
| Revenue CAGR (3y) | -43.3% | - | -38.8% | -38.5% | -34.8% | - | -30.3% | -24.7% | -20.0% | - |
| Revenue CAGR (5y) | -25.9% | - | -19.9% | -13.7% | -8.3% | - | -5.9% | -2.1% | 1.0% | - |
| Gross profit growth (YoY) | -38.6% | - | -41.2% | -37.9% | -33.8% | - | -40.4% | -41.4% | -48.3% | - |
| Operating income growth (YoY) | -161.1% | - | - | 86.5% | - | - | -91.7% | - | -85.2% | - |
| Net income growth (YoY) | -174.9% | - | - | - | - | - | -95.1% | - | -79.2% | - |
| EPS growth (YoY) | -171.4% | - | - | - | - | - | -95.3% | - | -79.3% | - |
| EPS CAGR (3y) | - | - | - | -59.9% | - | - | -69.6% | - | -39.7% | - |
| EPS CAGR (5y) | - | - | - | -34.7% | - | - | -40.3% | - | -14.9% | - |
| FCF growth (YoY) | - | - | - | - | -65.4% | - | - | - | -91.2% | - |
| FCF CAGR (5y) | - | - | - | - | -41.0% | - | - | - | -28.1% | - |
| Book value growth (YoY) | -6.3% | -5.3% | 3.6% | 5.2% | -0.0% | 4.3% | 7.4% | 10.6% | 23.4% | 30.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$385.79M totalOptavia Segment$385.79M · 100.0%
Peer comparison
Same SIC group: Miscellaneous Food Preparations & Kindred Products
Comparing MEDIFAST INC against the 5 most active filers in the same SIC group.
Dividends
$0.00/share trailing 12 months
| Ex-date | Per share |
|---|---|
| Sep 18, 2023 | $1.6500 |
| Jun 26, 2023 | $1.6500 |
| Mar 27, 2023 | $1.6500 |
| Dec 19, 2022 | $1.6400 |
| Sep 19, 2022 | $1.6400 |
| Jun 27, 2022 | $1.6400 |
| Mar 28, 2022 | $1.6400 |
| Dec 20, 2021 | $1.4200 |
| Sep 20, 2021 | $1.4200 |
| Jun 21, 2021 | $1.4200 |
| Mar 29, 2021 | $1.4200 |
| Dec 21, 2020 | $1.1300 |
| Sep 21, 2020 | $1.1300 |
| Jun 29, 2020 | $1.1300 |
| Mar 30, 2020 | $1.1300 |
| Dec 26, 2019 | $1.1300 |
| Sep 26, 2019 | $0.7500 |
| Jun 27, 2019 | $0.7500 |
| Mar 28, 2019 | $0.7500 |
| Dec 20, 2018 | $0.7500 |
| Sep 20, 2018 | $0.4800 |
| Jun 28, 2018 | $0.4800 |
| Mar 28, 2018 | $0.4800 |
| Dec 21, 2017 | $0.4800 |